Why the study?
Hyperkalemia often leads to reducing or discontinuing guideline-directed RAASi and MRA therapy in cardiovascular disease, prompting the need for alternative strategies to manage hyperkalemia and maintain therapy.
New strategies for managing hyperkalemia allow for the continuation of guideline-directed RAASi and MRA therapies in patients with cardiovascular and renal diseases, avoiding suboptimal management.
Answers are grounded in this paper and cite their sources.
Hyperkalaemia risk with RAASi/MRAs warrants monitoring in CVD; leaves open optimal mitigation strategies.
Renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) are key drugs in the management of patients with cardiovascular diseases (CVD), particularly those with hypertension, diabetes, chronic kidney disease and heart failure (HF), given their demonstrated effectiveness in reducing the risk of both surrogate and hard endpoints. Despite their positive impact on the outcome, patients with RAASi and MRAs are particularly vulnerable to hyperkalaemia, with approximately 50 % of these individuals experiencing two or more recurrences annually. The common practice of reducing the dose or discontinuing the treatment with RAASi and MRAs in conditions of hyperkalaemia results in suboptimal management of these patients, with a potential impact on their mortality and morbidity risk. Recent guidelines from cardiovascular and renal international societies increasingly recognize the need for alternative strategies to manage the risk of hyperkalaemia, allowing the continuation of RAASi and MRA therapies. In this review, we summarise the new potential options available to manage hyperkalaemia in patients with CVD and the recommendations of the most recent guidelines on the topic.
No takes yet. Share an insight, caveat, or question.
Masi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: